Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995401 | 0.85 | USP30 (0.42) | USP30HPGDUSP2SMN1; SMN2ADORA1 | |
| SCHEMBL1441490 | 0.85 | USP30 (0.46) | USP30HPGDUSP2SMN1; SMN2KMT2A | |
| SCHEMBL619446 | 0.83 | SMN1; SMN2 (0.44) | USP30HPGDL3MBTL1USP2SMN1; SMN2 | |
| SCHEMBL30453762 | 0.83 | HPGD (0.39) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL21749171 | 0.83 | HPGD (0.42) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL30453434 | 0.83 | HPGD (0.39) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL2891521 | 0.83 | HPGD (0.39) | HPGDL3MBTL1USP2SMN1; SMN2ADORA1 | |
| SCHEMBL21749194 | 0.82 | L3MBTL1 (0.45) | L3MBTL1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL1439256 | 0.82 | USP30 (0.45) | USP30HPGDUSP2SMN1; SMN2KMT2A | |
| SCHEMBL19437400 | 0.82 | KMT2A (0.40) | L3MBTL1KMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-108884083-B | Benzo [ B ] furans as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-108884070-B | Pyridyl derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| EP-3440075-B1 | BENZO[B]FURANS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | USP30 2775/4885HPGD 214/4885L3MBTL1 4308/4885 |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, CHRM4, CHRM5 | USP30 4190/4885HPGD 824/4885L3MBTL1 4576/4885 |
| US-10583112-B2 | Benzo[b]furans as bromodomain inhibitors | BRD4, BRD3, BRD2 | USP30 1651/4885HPGD 234/4885L3MBTL1 4361/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | USP30 4127/4885HPGD 229/4885L3MBTL1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.